The business model sounds almost quaint in its audacity: Pay us first, and then—only then—we'll tell you which medicinal plant might help your ulcer, or your fibroids, or your cancer.
That's the unusual wager behind eSelfcare, a mobile app from Choroids Limited that recently entered Nigeria's crowded and often chaotic digital health market. The premise is simple enough. Type in a condition. Browse some options. Tap "pay." Only after the transaction clears does the app reveal which plant it recommends, alongside warnings about side effects and potential clashes with conventional drugs.
It's not telemedicine, exactly. Not e-commerce either, at least not in the traditional sense. Call it information arbitrage with a paywall—betting that Nigerians will fork over money for curated herbal guidance in a country where traditional medicine already flourishes, though often without much in the way of safety nets.
The Gatekeeping Problem
What makes eSelfcare unusual, perhaps more than its founders intended, is the sequence. Most health apps let you browse freely before asking for payment. Symptom checkers, herb databases, wellness platforms—they tend to lead with transparency. You see what you're getting, then decide whether it's worth your cash or your data.
eSelfcare flips that. According to a feature that ran in Guardian Nigeria shortly after the app's Android launch, users commit financially before learning which plant the algorithm has selected or understanding the safety profile attached to it. The app's Google Play listing confirms in-app billing permissions, though no specific public pricing has been disclosed. Neither Choroids nor the eSelfcare website spell out the costs. At least not publicly, and not as of this writing.
The company describes its content as "scientifically valid" and "validated by humans." Fair enough. But the methodology? The evidence sources? Partnerships with pharmacopeia, research institutions, or academic bodies? Those details remain conspicuously absent from public view. Maruf Aminu, identified as the founder in a Guardian op-ed, frames the mission as de-risking plant-based self-care. The transparency layer to back that up, though—citations, clinical references, third-party audits—hasn't materialized yet.
A Company With Many Addresses
Choroids Limited was registered in Nigeria in 2026, according to the Guardian piece. But the corporate footprint is wider and, frankly, a bit puzzling. The Google Play developer profile lists Choroids LLC, a Wyoming-based entity with a Sheridan address—a detail that raises eyebrows in a country where foreign-registered startups sometimes inspire skepticism. The company's website, meanwhile, claims offices in Phoenix and Uzbekistan's Fergana region. The app's About page references teams in the United States, Nigeria, and Pakistan.
No headcount. No org chart. No explanation of how these pieces fit together.
Last fall, Choroids secured a German Utility Model for eSelfcare—file number 202025104015.8—through the German Patent and Trademark Office. Utility models in Germany are faster and cheaper than patents, partly because they skip substantive examination. They're easier to get. They're also less rigorous.
Regulation? Not Quite Yet
eSelfcare positions itself as an informational tool, not a medical device or drug, according to its Play Store description. Both the Play Store listing and the app's homepage emphasize that the content is "not a substitute for professional healthcare services." It's a familiar hedge, one that might keep the app outside the reach of Nigeria's National Agency for Food and Drug Administration and Control—NAFDAC—which has recently demanded clinical trials for herbal medicines seeking full approval, though NAFDAC has not publicly commented on the app's regulatory status.
Apps delivering paid health information, though, occupy a murkier regulatory space. And Nigeria is tightening the screws. Late last year, the House of Representatives advanced legislation to strengthen NAFDAC's explicit mandate over herbal medicines. Around the same time, Al Jazeera ran a piece highlighting concerns about Nigeria's "algorithmic apothecary"—online platforms fueling risky self-medication with herbs, though without specific reference to eSelfcare.
The regulatory conversation is moving in eSelfcare's direction. It just hasn't arrived yet.
Early Numbers, and an iPhone Wait
As of early reports, the Android app had logged more than 1,000 downloads, according to Google Play's public install band—a modest start, though not unusual for a niche health tool in its first weeks. The listing shows the app was updated shortly after the Guardian announcement. Version 1.0.10 weighs in at roughly 114 MB, per third-party tracking data.
An iOS version remains under Apple review, according to the same Guardian feature. The eSelfcare site still reads "Coming soon on iOS." No App Store listing had appeared at the time of the initial coverage.
A Crowded Field
Nigeria's digital health scene already includes telemedicine platforms like EzzyCare, emergency response tools like Vivo Health, and herb-focused apps such as Ewé, which preserves Yoruba medicinal knowledge with an AI-powered plant scanner. eSelfcare differentiates itself by pairing condition-specific plant recommendations with safety data—a worthwhile idea, on paper.
But the paid gating and the lack of public evidence sources set it apart in ways that cut both directions. Compare it to the U.S. National Institutes of Health's HerbList app, which launched several years ago with evidence-based profiles for more than 50 herbs, all freely accessible. Or free herbal databases that don't demand payment before revealing their contents.
Choroids has disclosed no venture funding, no grants, no investors. The company's bet is that Nigeria's appetite for plant-based remedies, combined with rising smartphone adoption, will support a premium information layer. Whether that wager pays off depends on something harder to quantify: user trust.
And trust, in health tech, tends to require transparency. Which means Choroids may need to show its work—before someone else forces the issue.
